ENDRA Life Sciences Inc.
NDRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -21.81 | 63.41 | 78.58 |
| FCF Yield | -105.55% | -0.15% | -0.09% | -0.02% |
| EV / EBITDA | -0.41 | -647.34 | -1,061.77 | -4,500.33 |
| Quality | ||||
| ROIC | -274.26% | -173.80% | -169.75% | -99.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.64 | 0.95 | 0.97 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 22.60% | 26.13% | -16.16% | -3.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.25 | 0.34 | 0.79 |
| Interest Coverage | 0.00 | 0.00 | -611.04 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.09 | 0.17 |
| Cash Conversion Cycle | 0.00 | -477.57 | 3,164.14 | 802.70 |